MKI67 and breast carcinoma: Ma et al. [42] developed an ML system to differentiate luminal/HER 2+/TNBC/versus other subtypes, ER-positive versus ER-negative, HER2-positive versus HER2-negative, and high Ki-67 versus low Ki-67 expression, proving that a machine learning model can assist radiologists to evaluate the molecular subtype of breast cancer.